NICE:
The agenda for the Technology Appraisal Committee C meeting for Tuesday 15 January 2013 will be live on the NICE website on Thursday 6 December 2012. The Appraisal Committee will discuss a Rapid Review of Dasatinib of published guidance Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70) (RAPID REVIEW of TA251), Patient Access Schemes (PAS) submitted through the rapid review facility are considered ‘commercial in confidence’ and all matters, relating to the scheme (except the existence of the scheme proposal).
The agenda for the Technology Appraisal Committee C meeting for Tuesday 15 January 2013 will be live on the NICE website on Thursday 6 December 2012.